At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 27, 2026 at 10:30 ET
Palvella Therapeutics presented two posters at the 2026 American Academy of Dermatology meeting: one highlighting the technical advantages and clinical success of its QTORIN™ rapamycin gel in treating rare skin diseases, and another detailing the significant patient burden of porokeratosis, a rare genetic skin condition with no FDA-approved therapies. The company is advancing QTORIN™ rapamycin through Phase 3 trials and plans to initiate a Phase 2 trial for QTORIN™ pitavastatin in porokeratosis in the second half of 2026.
- QTORIN™ rapamycin met primary and all secondary endpoints in the Phase 3 SELVA study for microcystic lymphatic malformations (p<0.001).
- Systemic rapamycin levels remained below 2 ng/mL, indicating favorable safety and localized delivery.
- Poster #76929 highlights substantial physical, psychosocial, and cancer-related burdens in porokeratosis patients based on 10 qualitative interviews.
- No FDA-approved therapies currently exist for porokeratosis, affecting over 50,000 diagnosed U.S. patients.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access